The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions. - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer. - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent. - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised. - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
Checkpoint kinase 2
Checkpoint like protein CHK2
CHK2 checkpoint homolog
CHK2 checkpoint homolog (S. pombe)
Serine/threonine protein kinase Chk2
Serine/threonine-protein kinase Chk2
Regulates cell cycle checkpoints and apoptosis in response to DNA damage, particularly to DNA double-strand breaks. Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', preventing the entry into mitosis. May also play a role in meiosis. Regulates the TP53 tumor suppressor through phosphorylation at 'Thr-18' and 'Ser-20'.
High expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.
Involvement in disease
Defects in CHEK2 are associated with Li-Fraumeni syndrome 2 (LFS2) [MIM:609265]; a highly penetrant familial cancer phenotype usually associated with inherited mutations in p53/TP53. Defects in CHEK2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Defects in CHEK2 are found in some patients with osteogenic sarcoma (OSRC) [MIM:259500].
Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CHK2 subfamily. Contains 1 FHA domain. Contains 1 protein kinase domain.
Phosphorylated by PLK4.
Nucleus; Nucleus. Isoform 10 is present throughout the cell and Nucleus > PML body. Nucleus > nucleoplasm. Recruited into PML bodies together with TP53.
Western blot - Chk2 (phospho T26) antibody (ab26338)
All lanes : Anti-Chk2 (phospho T26) antibody (ab26338) at 1 µg/ml
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg Lane 2 : Gamma-Irradiated HeLa Lysate - 4 hour exposure at 20 µg Lane 3 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg with Human Chk2 (phospho T26) peptide (ab27902) at 1 µg/ml Lane 4 : Gamma-Irradiated HeLa Lysate - 4 hour exposure at 20 µg with Human Chk2 (phospho T26) peptide (ab27902) at 1 µg/ml Lane 5 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg with Human Chk2 peptide (ab37237) at 1 µg/ml Lane 6 : Gamma-Irradiated HeLa Lysate - 4 hour exposure at 20 µg with Human Chk2 peptide (ab37237) at 1 µg/ml